

Mario Roselli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3559728/publications.pdf>

Version: 2024-02-01

59
papers

1,671
citations

331259

21
h-index

301761

39
g-index

59
all docs

59
docs citations

59
times ranked

2979
citing authors

#	ARTICLE	IF	CITATIONS
1	Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2020, 21, 497-507.	5.1	196
2	Obesity and colorectal cancer: Role of adipokines in tumor initiation and progression. <i>World Journal of Gastroenterology</i> , 2014, 20, 5177.	1.4	157
3	Effects of conventional therapeutic interventions on the number and function of regulatory T cells. <i>Oncolmmunology</i> , 2013, 2, e27025.	2.1	148
4	Phase angle as bioelectrical marker to identify elderly patients at risk of sarcopenia. <i>Experimental Gerontology</i> , 2014, 58, 43-46.	1.2	125
5	Breast Cancer Prognosis Using a Machine Learning Approach. <i>Cancers</i> , 2019, 11, 328.	1.7	101
6	Overexpression of the EMT Driver Brachyury in Breast Carcinomas: Association With Poor Prognosis. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	3.0	65
7	Type 2 Diabetes and Breast Cancer: The Interplay between Impaired Glucose Metabolism and Oxidant Stress. <i>Oxidative Medicine and Cellular Longevity</i> , 2015, 2015, 1-10.	1.9	63
8	Risk Assessment for Venous Thromboembolism in Chemotherapy-Treated Ambulatory Cancer Patients. <i>Medical Decision Making</i> , 2017, 37, 234-242.	1.2	63
9	Global mapping of cancers: The Cancer Genome Atlas and beyond. <i>Molecular Oncology</i> , 2021, 15, 2823-2840.	2.1	55
10	Pretreatment Insulin Levels as a Prognostic Factor for Breast Cancer Progression. <i>Oncologist</i> , 2016, 21, 1041-1049.	1.9	49
11	Validation of a Machine Learning Approach for Venous Thromboembolism Risk Prediction in Oncology. <i>Disease Markers</i> , 2017, 2017, 1-7.	0.6	49
12	Anti-PD-L1/TGF β 2R2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 93.e1-93.e11.	0.8	40
13	Predicting VTE in Cancer Patients: Candidate Biomarkers and Risk Assessment Models. <i>Cancers</i> , 2019, 11, 95.	1.7	33
14	Brachyury, a vaccine target, is overexpressed in triple-negative breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, 783-796.	1.6	31
15	Butyryl-cholinesterase is related to muscle mass and strength. A new biomarker to identify elderly subjects at risk of sarcopenia. <i>Biomarkers in Medicine</i> , 2015, 9, 669-678.	0.6	28
16	Impact of chemotherapy on activated protein C α -dependent thrombin generation α Association with VTE occurrence. <i>International Journal of Cancer</i> , 2013, 133, 1253-1258.	2.3	26
17	The association of clinical outcome and peripheral T-cell subsets in metastatic colorectal cancer patients receiving first-line FOLFIRI plus bevacizumab therapy. <i>Oncolmmunology</i> , 2016, 5, e1188243.	2.1	26
18	Oxidant stress as a major determinant of platelet activation in invasive breast cancer. <i>International Journal of Cancer</i> , 2017, 140, 696-704.	2.3	24

#	ARTICLE	IF	CITATIONS
19	Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials. <i>Journal of Bone Oncology</i> , 2019, 18, 100252.	1.0	23
20	Ketogenic Diet and Other Dietary Intervention Strategies in the Treatment of Cancer. <i>Current Medicinal Chemistry</i> , 2017, 24, 1170-1185.	1.2	23
21	Issues and promises of bevacizumab in prostate cancer treatment. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 707-717.	1.4	22
22	Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy. <i>Haematologica</i> , 2014, 99, 1638-1644.	1.7	20
23	Recent perspective on CAR and Fcγ3-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes. <i>Biochemical Pharmacology</i> , 2019, 166, 335-346.	2.0	20
24	Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence. <i>Journal of Cellular Physiology</i> , 2020, 235, 7900-7910.	2.0	19
25	Prognostic Significance of Neutrophil-to-lymphocyte Ratio in the Framework of the 8th TNM Edition for Breast Cancer. <i>Anticancer Research</i> , 2018, 38, 4705-4712.	0.5	16
26	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. <i>Oncotarget</i> , 2017, 8, 41641-41669.	0.8	15
27	CD161-expressing chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab. <i>International Journal of Cancer</i> , 2020, 146, 2531-2538.	2.3	15
28	Urine LOX-1 and Volatilome as Promising Tools towards the Early Detection of Renal Cancer. <i>Cancers</i> , 2021, 13, 4213.	1.7	15
29	Gastric Inflammatory Prognostic Index (GIPI) in Patients with Metastatic Gastro-Esophageal Junction/Gastric Cancer Treated with PD-1/PD-L1 Immune Checkpoint Inhibitors. <i>Targeted Oncology</i> , 2020, 15, 327-336.	1.7	15
30	Targeted therapy in first line treatment of RAS wild type colorectal cancer. <i>World Journal of Gastroenterology</i> , 2015, 21, 2871.	1.4	14
31	Neutrophil/lymphocyte ratio helps select metastatic pancreatic cancer patients benefitting from oxaliplatin. <i>Cancer Biomarkers</i> , 2016, 17, 335-345.	0.8	13
32	Bevacizumab as First-Line Treatment in HER2-Negative Advanced Breast Cancer: Pros and Cons. <i>Tumori</i> , 2016, 102, 472-480.	0.6	12
33	Sex-Genetic Interaction in the Risk for Cerebrovascular Disease. <i>Current Medicinal Chemistry</i> , 2017, 24, 2687-2699.	1.2	12
34	Anti-Angiogenic Drugs, Vascular Toxicity and Thromboembolism in Solid Cancer. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2017, 15, 3-16.	0.4	12
35	Artificial intelligence for cancer-associated thrombosis risk assessment. <i>Lancet Haematology</i> , 2018, 5, e391.	2.2	11
36	Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. <i>Biology Direct</i> , 2022, 17, .	1.9	11

#	ARTICLE	IF	CITATIONS
37	Clinical Utility of Plasma KRAS, NRAS and BRAF Mutational Analysis with Real Time PCR in Metastatic Colorectal Cancer Patients – The Importance of Tissue/Plasma Discordant Cases. <i>Journal of Clinical Medicine</i> , 2021, 10, 87.	1.0	10
38	Insulin resistance as a predictor of venous thromboembolism in breast cancer. <i>Endocrine-Related Cancer</i> , 2016, 23, L25-L28.	1.6	9
39	Gender Differences in Cancer-associated Venous Thromboembolism. <i>Current Medicinal Chemistry</i> , 2017, 24, 2589-2601.	1.2	9
40	Factors influencing diagnostic accuracy of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) in pancreatic and biliary tumors. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 498-504.	0.6	8
41	The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial. <i>Scientific Reports</i> , 2021, 11, 13770.	1.6	8
42	Activity of ALK Inhibitors in Renal Cancer with ALK Alterations: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3995.	1.8	8
43	Insulin Resistance as a Risk Factor for Cutaneous Melanoma. A Case Control Study and Risk-Assessment Nomograms. <i>Frontiers in Endocrinology</i> , 2019, 10, 757.	1.5	6
44	Breast Cancer Is Associated with Increased HLA-DRB1*11:01 and HLA-DRB1*10:01 Allele Frequency in a Population of Patients from Central Italy. <i>Immunological Investigations</i> , 2020, 49, 489-497.	1.0	6
45	Ensuring Sample Quality for Biomarker Discovery Studies - Use of ICT Tools to Trace Biosample Life-cycle. <i>Cancer Genomics and Proteomics</i> , 2015, 12, 291-9.	1.0	6
46	Drug-induced xenogenization of tumors: A possible role in the immune control of malignant cell growth in the brain?. <i>Pharmacological Research</i> , 2018, 131, 1-6.	3.1	5
47	Venous Thromboembolism in Cancer Patients on Simultaneous and Palliative Care. <i>Cancers</i> , 2020, 12, 1167.	1.7	5
48	A scoping review on the “burned out” or “burnt out” testicular cancer: When a rare phenomenon deserves more attention. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 165, 103452.	2.0	5
49	Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting. <i>International Journal of Cancer</i> , 2020, 146, 1917-1929.	2.3	4
50	Precision medicine in the ageing world: The role of biospecimen sciences. <i>International Journal of Biological Markers</i> , 2019, 34, 3-5.	0.7	3
51	Endoscopic Ultrasound Plus Endoscopic Retrograde Cholangiopancreatography Based Tissue Sampling for Diagnosis of Proximal and Distal Biliary Stenosis Due to Cholangiocarcinoma: Results from a Retrospective Single-Center Study. <i>Cancers</i> , 2022, 14, 1730.	1.7	3
52	Immune Response in Vitamin D Deficient Metastatic Colorectal Cancer Patients: A Player That Should Be Considered for Targeted Vitamin D Supplementation. <i>Cancers</i> , 2022, 14, 2594.	1.7	3
53	Hemoglobin level and XRCC1 polymorphisms to select patients with locally advanced rectal cancer candidate for neoadjuvant chemoradiotherapy with concurrent capecitabine and a platinum salt. <i>Medical Oncology</i> , 2018, 35, 83.	1.2	1
54	Case Report of a Patient with Breast Metastasis from Gastric Cancer Treated with Paclitaxel and Ramucirumab Plus Regional Hyperthermia. <i>Anticancer Research</i> , 2018, 38, 6561-6564.	0.5	1

#	ARTICLE	IF	CITATIONS
55	Risk Prediction and New Prophylaxis Strategies for Thromboembolism in Cancer. <i>Cancers</i> , 2021, 13, 1556.	1.7	1
56	Irinotecan or Oxaliplatin: Which is the First Move for the Mate?. <i>Current Medicinal Chemistry</i> , 2021, 28, 3158-3172.	1.2	1
57	Functional impairment of activated protein C in breast cancer - relationship to survival outcomes. <i>American Journal of Cancer Research</i> , 2016, 6, 1450-7.	1.4	1
58	MiRNAs and circRNAs for the Diagnosis of Anthracycline-Induced Cardiotoxicity in Breast Cancer Patients: A Narrative Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 1059.	1.1	1
59	VEGF and VTE Risk in Cancer Patientsâ€™ Letter. <i>Clinical Cancer Research</i> , 2016, 22, 1295-1295.	3.2	0